Successful exclusion of an aortic aneurysm with a novel PTFE‐tube covered cobalt‐chromium stent in a pediatric patient with native coarctation of the aorta

Nordmeyer, Johannes; Krämer, Peter; Berger, Felix; Schubert, Stephan

doi:10.1002/ccd.27647

Cited by 10 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interventional treatment of CoA by stent implantation is one of the most challenging procedures for cardiologists and choosing the appropriate stent is essential. Covered stents have been preferred over the years, as they may minimize aortic wall injury 14,15 and have a role in those CoAs associated with aneurysms or patent ductus arteriosus (PDA) 4,16 . The BeGraft Aortic stent is available in Europe, wide parts of Asia, Latin America and Africa.…”

Section: Discussionmentioning

confidence: 99%

“…There is limited information of the feasibility and outcome of CoA treatment with the BeGraft Aortic stent, except a single case report of successful exclusion of a complex aortic aneurysm associated with CoA in a 11‐year‐old boy with this stent 4 . The other experience in non‐congenital lesion showed favorable outcome in sealing the proximal common iliac artery in treating isolated common iliac artery aneurysm combined with iliac branch device 5 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

Promphan

Siang

Prachasilchai

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives To assess feasibility and early outcomes of using BeGraft Aortic stent in the treatment of aortic coarctation (CoA). Background BeGraft Aortic stent (Bentley InnoMed, Hechingen, Germany) allows large postdilation diameter up to 30 mm. With availability of lengths of 19–59 mm and lower stent profile, they can be used in native and recurrent CoA in adults and in pediatric patients. Materials and methods This is a multicentre retrospective analysis of 12 implanted BeGraft Aortic stents in CoA between May 2017 and April 2019. Results Twelve patients aged 7.7–38 years (median 18.3 years) with body weight of 19.9–56 kg (median 45.5 kg). Eight patients (66%) had native juxtaductal CoA while four had recurrent CoA after previous surgical or transcatheter treatments. The stents were implanted successfully in all the patients with no serious adverse events. The length of the stents ranged from 27 to 59 mm and the implanted stent diameter varied from 12 to 18 mm. The median intraprocedural CoA pressure gradient decreased from 25 mmHg (range 16–66 mmHg) to 2 mmHg (range 0–13 mmHg). The mean follow‐up duration was 10.2 months. Two patient (16.6%) had residual stent narrowing requiring staged redilation. One patient (8%) had pseudoaneurysm formation at 1 year cardiac CT follow‐up. Conclusions The BeGraft Aortic stent may be considered to be safe and effective in the short term in treatment of CoA from childhood to adulthood. Long‐term follow‐up is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

Promphan

Siang

Prachasilchai

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…This study adds to the growing body of literature which shows that 3D CT or MRI overlay for CHD transcatheter intervention with rapid registration is feasible and aids decisions regarding access and planned angiographic angles. [1][2][3][7][8][9] Novel applications of imaging overlay technology in this study include thoracic duct interventions (Fig 4) as well as a right coronary artery fistula occlusion. This information is further outlined in Tables 2 and 3.…”

Section: Discussionmentioning

confidence: 99%

3D advanced imaging overlay with rapid registration in CHD to reduce radiation and assist cardiac catheterisation interventions

et al. 2020

View full text Add to dashboard Cite

Novel commercially available software has enabled registration of both CT and MRI images to rapidly fuse with X-ray fluoroscopic imaging. We describe our initial experience performing cardiac catheterisations with the guidance of 3D imaging overlay using the VesselNavigator system (Philips Healthcare, Best, NL). A total of 33 patients with CHD were included in our study. Demographic, advanced imaging, and catheterisation data were collected between 1 December, 2016 and 31 January, 2019. We report successful use of this technology in both diagnostic and interventional cases such as placing stents and percutaneous valves, performing angioplasties, occlusion of collaterals, and guidance for lymphatic interventions. In addition, radiation exposure was markedly decreased when comparing our 10–15-year-old coarctation of the aorta stent angioplasty cohort to cases without the use of overlay technology and the most recently published national radiation dose benchmarks. No complications were encountered due to the application of overlay technology. 3D CT or MRI overlay for CHD intervention with rapid registration is feasible and aids decisions regarding access and planned angiographic angles. Operators found intraprocedural overlay fusion registration using placed vessel guidewires to be more accurate than attempts using bony structures.

show abstract

“…The systems are much more simple, especially for 3DRA. There are newer technologies for use of other modalities such as MRI, CT and transesophageal echo fusion that have been developed, and especially the Siemens system and the Philips VesselNavigator are quite user friendly [45][46][47][48][49][50][51][52][53][54]. Hopefully as we continue to develop programs utilizing these technologies it will make our procedures much simpler for the operator.…”

Section: Sebastian Gorecznymentioning

confidence: 99%

Pros, cons and future perspectives – three questions on three dimensional guidance for cardiac catheterization in congenital heart disease

Góreczny

Krings

Hijazi

et al. 2019

pwki

View full text Add to dashboard Cite

Step changes in angiographic imaging are not commonplace. Since the move from analogue to digital and flat detector plates, two-dimensional imaging technology has certainly evolved but not jumped forward. Of all the routine imaging techniques used in cardiology, angiography has been the last modality to embrace the third dimension. Although the development of rotational angiography was initially for the benefit of neuroimaging and fusion of cross sectional datasets was aimed at the treatment of descending aortic pathology, interventional physicians in congenital and structural cardiology have immersed themselves in this technology over the last 10 years. Like many disruptive technologies, its introduction has divided opinion. We aimed to explore the mindset of those in the field of interventional cardiology who are driving imaging forward. These structured interviews recorded during the 21 st Pediatric and Adult Interventional Cardiac Symposium illustrate the challenges and sticking points as well as giving an insight into the direction of travel for three-dimensional imaging and fusion techniques. Covering a wide range of career development, seniority and experience, the interviewees in this article are probably responsible for the majority of the published literature on invasive three-dimensional imaging in congenital heart disease.

show abstract

Successful exclusion of an aortic aneurysm with a novel PTFE‐tube covered cobalt‐chromium stent in a pediatric patient with native coarctation of the aorta

Cited by 10 publications

References 11 publications

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

3D advanced imaging overlay with rapid registration in CHD to reduce radiation and assist cardiac catheterisation interventions

Pros, cons and future perspectives – three questions on three dimensional guidance for cardiac catheterization in congenital heart disease

Contact Info

Product

Resources

About